Extended Abstract
Author: Kimberly K. Leslie (University of Iowa)
A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer.
Keywords: Gefitinib; endometrial cancer; epidermal growth factor receptor (EGFR); soluble EGFR; estrogen receptor; progesterone receptor
How to Cite: Leslie, K. K. (2013) “A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study*”, Proceedings in Obstetrics and Gynecology. 3(4). doi: https://doi.org/10.17077/2154-4751.1226